FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to deuterated heterocyclic condensed gamma-carbolines of formulas I, II, III, in free or salt form, as well as their pharmaceutical compositions based on said compounds, to methods of treating diseases associated with 5-HT2A receptor, a serotonin transporter (SERT) and/or routes involving dopamine D1/D2 signaling system, and/or treating residual symptoms.
EFFECT: there are prepared and described compounds which demonstrate improved metabolic stability and can be used in treating disorders of the central nervous system.
20 cl, 2 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
ORGANIC COMPOUNDS | 2011 |
|
RU2591194C2 |
ORGANIC COMPOUNDS | 2017 |
|
RU2743513C2 |
PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OR PREVENTION OF DISORDER OF CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2776800C2 |
ORGANIC COMPOUNDS | 2018 |
|
RU2780002C2 |
NEW COMPOSITIONS AND METHODS | 2018 |
|
RU2767410C2 |
ORGANIC COMPOUNDS | 2018 |
|
RU2777366C2 |
ORGANIC COMPOUNDS | 2015 |
|
RU2785871C2 |
ORGANIC COMPOUNDS | 2015 |
|
RU2728787C2 |
SYNTHESIS OF SUBSTITUTED GAMMA-CARBOLINES CONDENSED WITH A HETEROCYCLE | 2019 |
|
RU2795581C2 |
NEW METHODS | 2014 |
|
RU2682658C1 |
Authors
Dates
2020-10-08—Published
2017-03-24—Filed